Summary & Overview
HCPCS J0802: Corticotropin (ani) Injection, Up to 40 Units
HCPCS Level II code J0802 denotes an injection of corticotropin (ani), up to 40 units, used in clinical settings where adrenocorticotropic hormone preparations are indicated. This code is important nationally because it identifies a specific injectable biologic product for billing, coverage determinations, and utilization tracking across outpatient and office-based care. Payers commonly engaged in coverage and payment decisions for this code include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise briefing on the clinical context for corticotropin injections, the typical sites of service where J0802 claims arise, and the payer landscape affecting coverage and reimbursement. The publication summarizes benchmark considerations, common billing practices, and policy trends relevant to injectable biologics coded via HCPCS Level II. Where available, the analysis highlights reimbursement benchmarks and coding guidance that impact billing workflows and prior authorization requirements. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J0802 represents an injection of corticotropin (ani), up to 40 units. This code covers the administration of corticotropin as a drug product supplied and injected to the patient.
-
Service type: Drug administration (injectable pharmaceutical)
-
Typical site of service: Physician office, outpatient clinic, or hospital outpatient department
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with moderate to severe inflammatory conditions (such as refractory rheumatoid arthritis, certain nephrotic syndromes, or inflammatory dermatoses) receives a clinic-administered preparation of corticotropin (repository ACTH, brand / formulation indicated by J0802) as an intramuscular or subcutaneous injection. The typical workflow begins with a physician evaluation documenting the indication and prior therapy failures or contraindications to standard treatments. Pharmacy prepares the medication per manufacturer instructions and the nurse verifies dose (units up to 40 units as billed with J0802), performs patient identification and allergy checks, and obtains informed consent for injection. The injection is administered in an outpatient infusion/injection suite or office procedure room. Post-injection, the patient is observed for immediate adverse reactions (vital signs and assessment for hypersensitivity) for a short period, education is provided about expected effects and adverse events (eg, fluid retention, hyperglycemia, hypertension), and follow-up is arranged with the ordering provider to assess therapeutic response and need for repeat dosing. Typical sites of service include hospital outpatient departments, ambulatory surgery centers when combined with other procedures, and physician offices or infusion clinics where injectable therapies are given.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |